Breaking News: MediPharm Labs Appoints Renowned Cannabis Researcher Dr. Landolt-Marticorena, MD, PhD, to its Science Advisory Committee

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that it has appointed renowned patient care and medical cannabis researcher, Dr. Carolina Landolt-Marticorena, MD, PhD, Structural Biochemistry, to its Science Advisory Committee (the “SAC”). Dr. Landolt-Marticorena also serves on the Cannabis Medical Advisory Board of Shoppers Drugmart.

“Dr. Landolt-Marticorena is an excellent addition who will further connect MediPharm Labs to the latest areas of cannabis research and help our organization to reach its potential as an active pharmaceutical ingredient provider and trusted manufacturer of advanced cannabinoid-based medicines,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.

“I believe strongly in the future of pharmaceutical-grade cannabinoid therapeutics and am excited to be joining MediPharm Labs’ Science Advisory Committee at this pivotal moment in the rapidly evolving cannabis industry,” said Dr. Carolina Landolt-Marticorena. “The success of developing these therapies will rely heavily on companies like MediPharm Labs to successfully purify individual cannabinoids so that we may study their effects in isolation and combinations to formulate precise cannabinoid treatments for a given diagnosis.”

“My principal focus is the development of novel cannabinoid therapeutic products by integrating basic scientific findings and clinical observations. MediPharm Labs’ commitment to supporting cannabis researchers is the ideal environment in which to pursue these objectives.”

Dr. Landolt-Marticorena Biography

Dr. Landolt-Marticorena is trained in internal medicine and rheumatology with a sub-specialization in the management of complex autoimmune disorders. Dr. Landolt-Marticorena completed a Research Fellowship and Chief Residency at the University of Toronto, and as a clinician-scientist, authoring multiple highly cited publications. She has held appointments at numerous Academic Institutions and Research Hospitals, garnering national and international awards at every stage of her career.

 In 2015 Dr. Landolt-Marticorena turned her focus to the emerging field of cannabinoid medicine establishing the first specialty-run clinic in Canada. Her practice focuses on the use of cannabinoids in the management of chronic pain conditions including degenerative and inflammatory arthritis, musculoskeletal and neuropathic pain and fibromyalgia. She has developed a unique expertise in this emerging area of medicine and is a sought-after academic speaker and public media expert. She is committed to developing accredited training programs for physicians and allied health care personnel, including for the University of Toronto Mitchener Institute, while also practicing Internal Medicine at Thunder Bay Regional Hospital.

About MediPharm Labs’ Science Advisory Committee

The SAC collaborates with MediPharm Labs’ management team on advancements in the emerging fields of cannabinoid extraction and cannabinoid-based derivative science. This work will serve to further enhance the Company’s manufacturing platform and research practices, assist management in evaluating commercial opportunities related to technologies, testing and methodologies and provide guidance on partnerships with globally preeminent academic and medical institutions for cannabis research.

The SAC’s mandate is to advise and assist MediPharm Labs in harnessing the potential of cannabis through innovation, best practices, thought leadership and strategic alliances in support of MediPharm Labs’ vision of being the Trusted Global Leader in Industrial-Scale Manufacturing of High-Quality, Cannabinoid-Based Derivatives.

For more information:

Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com 
Website: www.medipharmlabs.com

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely-dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.

Sponsored Content Release. Click for Full Disclosure

2 Comments
  1. Walt Newman 2 months ago
    Reply

    $LABS nicely consolidated above $5, next is breaking that mental resistance at $7.20

    • Robert Hamilton 2 months ago
      Reply

      $LABS covered short and long position initialized at 5.48 stop lower of the day, objective 5.7

Leave a Reply to Robert Hamilton Cancel reply

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corporation, financial and corporate news dissemination, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com..